Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SLEB1
MCID: SYS043
MIFTS: 38

Systemic Lupus Erythematosus 1 (SLEB1)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Systemic Lupus Erythematosus 1

About this section

MalaCards integrated aliases for Systemic Lupus Erythematosus 1:

Name: Systemic Lupus Erythematosus 1 57 72 29
Systemic Lupus Erythematosus, Resistance to 57 13
Sleb1 57 72
Systemic Lupus Erythematosus, Susceptibility to, 1 57
Lupus Erythematosus, Systemic, Type 1 39
Lupus Erythematosus, Systemic 70
Systemic Lupus Erythematosus 57

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Nephrological diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 601744
MeSH 44 D008180
UMLS 70 C0024141
Sources

Summaries for Systemic Lupus Erythematosus 1

About this section
UniProtKB/Swiss-Prot : 72 Systemic lupus erythematosus 1: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary : Systemic Lupus Erythematosus 1, also known as systemic lupus erythematosus, resistance to, is related to systemic lupus erythematosus 16 and systemic lupus erythematosus 2, and has symptoms including seizures and pruritus. An important gene associated with Systemic Lupus Erythematosus 1 is TLR5 (Toll Like Receptor 5). The drugs Atorvastatin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, skin and bone marrow.

More information from OMIM: 601744
Sources

Related Diseases for Systemic Lupus Erythematosus 1

About this section

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Systemic Lupus Erythematosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1975)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 11.9
2 systemic lupus erythematosus 2 11.8
3 systemic lupus erythematosus 10 11.8
4 systemic lupus erythematosus 9 11.8
5 systemic lupus erythematosus 6 11.8
6 systemic lupus erythematosus 11 11.8
7 vitiligo-associated multiple autoimmune disease susceptibility 1 11.7
8 systemic lupus erythematosus with hemolytic anemia 1 11.6
9 mixed connective tissue disease 11.6
10 neonatal systemic lupus erythematosus 11.6
11 neonatal lupus erythematosus 11.6
12 antiphospholipid syndrome 11.6
13 c1q deficiency 11.6
14 systemic lupus erythematosus 3 11.6
15 autoimmune disease 11.6
16 systemic lupus erythematosus 4 11.6
17 systemic lupus erythematosus 7 11.5
18 systemic lupus erythematosus 8 11.5
19 sjogren syndrome 11.5
20 systemic lupus erythematosus 15 11.5
21 systemic lupus erythematosus 13 11.5
22 systemic lupus erythematosus 5 11.5
23 systemic lupus erythematosus 12 11.5
24 systemic lupus erythematosus 14 11.5
25 systemic lupus erythematosus with nephritis 1 11.5
26 systemic lupus erythematosus with nephritis 2 11.5
27 pediatric systemic lupus erythematosus 11.5
28 systemic lupus erythematosus with nephritis 3 11.5
29 cutaneous lupus erythematosus 11.5
30 raynaud phenomenon 11.5
31 spondyloenchondrodysplasia with immune dysregulation 11.5
32 systemic scleroderma 11.4
33 complement component 2 deficiency 11.4
34 aicardi-goutieres syndrome 11.4
35 anemia, autoimmune hemolytic 11.4
36 fibromyalgia 11.4
37 vasculitis 11.4
38 drug-induced lupus erythematosus 11.3
39 exanthem 11.3
40 macrophage activation syndrome 11.3
41 neuromyelitis optica 11.3
42 nonbacterial thrombotic endocarditis 11.3
43 pure red-cell aplasia 11.3
44 progressive multifocal leukoencephalopathy 11.3
45 hypogonadotropic hypogonadism 11.3
46 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 11.3
47 undifferentiated connective tissue disease 11.3
48 glomerulonephritis 11.3
49 epidermolysis bullosa acquisita 11.3
50 rapidly progressive glomerulonephritis 11.3

Graphical network of the top 20 diseases related to Systemic Lupus Erythematosus 1:



Diseases related to Systemic Lupus Erythematosus 1
Sources

Symptoms & Phenotypes for Systemic Lupus Erythematosus 1

About this section

Clinical features from OMIM®:

601744 (Updated 05-Apr-2021)

UMLS symptoms related to Systemic Lupus Erythematosus 1:


seizures; pruritus
Sources

Drugs & Therapeutics for Systemic Lupus Erythematosus 1

About this section

Drugs for Systemic Lupus Erythematosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4 134523-00-5 60823
2
Metformin Approved Phase 4 657-24-9 4091 14219
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
4
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
5
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
6
Lifitegrast Approved Phase 4 1025967-78-5
7
belimumab Approved Phase 4 356547-88-1 5957 10451420
8
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
9
Sulfamethoxazole Approved Phase 4 723-46-6 5329
10
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
11
Simvastatin Approved Phase 4 79902-63-9 54454
12
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
13 Immunologic Factors Phase 4
14 Hypoglycemic Agents Phase 4
15 Cyclosporins Phase 4
16 Vaccines Phase 4
17 Antipyretics Phase 4
18 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
19 Omega 3 Fatty Acid Phase 4
20 Fibrinolytic Agents Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Platelet Aggregation Inhibitors Phase 4
23 Hydroxycholecalciferols Phase 4
24 Ibandronic Acid Phase 4
25 Rosuvastatin Calcium Phase 4 147098-20-2
26 Lubricant Eye Drops Phase 4
27 Complement System Proteins Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
30 Angiogenesis Inhibitors Phase 4
31 Complement C3 Phase 4
32 Antimetabolites Phase 4
33 Anticholesteremic Agents Phase 4
34 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
35 Lipid Regulating Agents Phase 4
36 Hypolipidemic Agents Phase 4
37
Ramipril Approved Phase 2, Phase 3 87333-19-5 5362129
38
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
39
Polyestradiol phosphate Approved Phase 3 28014-46-2
40
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
41
Norethindrone Approved Phase 3 68-22-4 6230
42
Ferrous fumarate Approved Phase 3 141-01-5
43
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
44
Warfarin Approved Phase 2, Phase 3 81-81-2 54678486 6691
45
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8
46
Mycophenolic acid Approved Phase 3 24280-93-1 446541
47
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
48
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
49
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
50
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 656)
# Name Status NCT ID Phase Drugs
1 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
2 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
6 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
7 A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus Completed NCT03098823 Phase 4 RAYOS;Prednisone
8 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
9 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Completed NCT02953821 Phase 4 Acthar Gel;Placebo Gel
10 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
11 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
12 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
13 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
14 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Completed NCT01753401 Phase 4 Acthar;Placebo;Steroid Drug
15 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
16 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
17 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
18 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
19 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
20 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
21 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
22 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
23 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
24 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
25 Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Completed NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
26 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
27 Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
28 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
29 A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus Recruiting NCT04127747 Phase 4 Standard dose of rituximab;Individualized dose of rituximab
30 Pilot Trial of Belimumab in Early Lupus Recruiting NCT03543839 Phase 4
31 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Active, not recruiting NCT01705977 Phase 4
32 Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study Not yet recruiting NCT04447053 Phase 4 Belimumab Injection [Benlysta]
33 Efficacy and Safety of Belimumab for Prevention of Disease Flares in SLE Patients With Low Disease Activity Not yet recruiting NCT04515719 Phase 4
34 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
35 The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria Withdrawn NCT00508898 Phase 4 Calcitriol;Multivitamin
36 Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus Withdrawn NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
37 The Effect of Milnacipran on Fatigue and Quality of Life in a Lupus Cohort Withdrawn NCT01359826 Phase 4 Milnacipran
38 Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease Withdrawn NCT01276782 Phase 4 Levothyroxine
39 Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial Withdrawn NCT04382625 Phase 4 Hydroxychloroquine
40 An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus Unknown status NCT00432354 Phase 2, Phase 3 atorvastatin
41 A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Unknown status NCT00053560 Phase 3 Prasterone (GL701)
42 Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus Unknown status NCT02444728 Phase 3 Hydroxychloroquine;Cyclophosphamide;Azathioprine;Methylprednisolone
43 Study of GL701 in Men With Systemic Lupus Erythematosus Unknown status NCT00037128 Phase 3 GL701
44 Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment (Prednisone 5 Milligram Per Day) in Quiescent Systemic Lupus Unknown status NCT02558517 Phase 3 prednisone discontinuation
45 Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial Unknown status NCT03178188 Phase 2, Phase 3
46 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus Completed NCT00004662 Phase 3 dehydroepiandrosterone
47 A Canadian Multicenter, Randomized, Double-Blind Placebo-Controlled Study of Methotrexate and Folic Acid in Systemic Lupus Erythematosus: A Phase III Trial. Completed NCT00470522 Phase 3 Methotrexate and folic acid
48 Ramipril Improves Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus: a Randomized and Controlled Study. Completed NCT03979976 Phase 2, Phase 3 Ramipril
49 Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus Completed NCT00004795 Phase 2, Phase 3 dehydroepiandrosterone
50 BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan Completed NCT01597622 Phase 3 Belimumab

Search NIH Clinical Center for Systemic Lupus Erythematosus 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Azathioprine
Cyclosporine
Hydroxychloroquine
Hydroxychloroquine Sulfate
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide
Sources

Genetic Tests for Systemic Lupus Erythematosus 1

About this section

Genetic tests related to Systemic Lupus Erythematosus 1:

# Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 1 29 TLR5
Sources

Anatomical Context for Systemic Lupus Erythematosus 1

About this section

MalaCards organs/tissues related to Systemic Lupus Erythematosus 1:

40
Endothelial, Skin, Bone Marrow, Bone, Eye, T Cells, Whole Blood
Sources

Publications for Systemic Lupus Erythematosus 1

About this section

Articles related to Systemic Lupus Erythematosus 1:

(show top 50) (show all 65)
# Title Authors PMID Year
1
A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. 6 57
16027372 2005
2
Impaired TLR5 functionality is associated with survival in melioidosis. 6
23447684 2013
3
Regulation of B cell tolerance by the lupus susceptibility gene Ly108. 57
16778059 2006
4
A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. 6
14623910 2003
5
The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. 57
11172029 2001
6
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. 57
9843982 1998
7
Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. 57
9502778 1998
8
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. 57
9045876 1997
9
Susceptibility loci for lupus: a guiding light from murine models? 57
9045853 1997
10
The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis. 61
33527798 2021
11
A Long-Term Follow-up of Retinal Vasculitis - Do They Develop Systemic Disease? 61
31906773 2020
12
Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. 61
31694743 2020
13
[Etiologies and risk factors for young people with intracerebral hemorrhage]. 61
30643071 2018
14
Gastrointestinal Tract Vasculopathy: Clinicopathology and Description of a Possible "New Entity" With Protean Features. 61
29624512 2018
15
Intramuscular Steroids in the Treatment of Dermatologic Disease: A Systematic Review. 61
29537450 2018
16
Yield of Screening Tests for Systemic Vasculitis in Young Adults with Ischemic Stroke. 61
30716738 2018
17
Etiological profile of noncompressive myelopathies in a tertiary care hospital of Northeast India. 61
28298841 2017
18
[Risk factors for long-term result of endovascular treatment for auto-immune disease related abdominal aorta pseudo-aneurysm]. 61
27978898 2016
19
Epidemiology of rheumatic diseases in Mixtec and Chontal indigenous communities in Mexico: a cross-sectional community-based study. 61
26689797 2016
20
Clinical features and outcome of acute exacerbation of interstitial pneumonia associated with connective tissue disease. 61
27644575 2016
21
Association of Extrahepatic Manifestations with Autoimmune Hepatitis. 61
26641498 2015
22
Autoantibodies against CD74 in spondyloarthritis. 61
23687263 2014
23
Corticoid-associated complications in elderly. 61
23197053 2012
24
Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. 61
22228484 2012
25
Sternal insufficiency fractures of post-menopausal women: retrospective analysis of 17 cases. 61
22770409 2012
26
[Retrospective evaluation of the ten-year experience of a single coeliac centre]. 61
22580504 2012
27
Evaluation of pulse wave velocity in systemic lupus erythematosus, rheumatoid arthritis and Behçet's disease. 61
22079854 2012
28
[Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions]. 61
21712172 2011
29
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. 61
19264918 2009
30
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. 61
17376507 2007
31
Subcellular localization of a germiantion-specific cortex-lytic enzyme, SleB, of Bacilli during sporulation. 61
16905870 2006
32
[Systemic lupus erythematosus presenting with a choreo-athetosic syndrome associated with antiphospholipid antibodies]. 61
16365627 2005
33
Several genes contribute to the production of autoreactive B and T cells in the murine lupus susceptibility locus Sle1c. 61
16002709 2005
34
Inflammatory aortic aneurysm is associated with increased incidence of autoimmune disease. 61
12947264 2003
35
Kikuchi's disease: a review and analysis of 61 cases. 61
12748557 2003
36
Malignant lymphoma-associated autoimmune diseases--a descriptive epidemiological study. 61
12426661 2002
37
[Role of anti-prothrombin in antiphospholipid syndrome]. 61
12404033 2002
38
[Prevalence and clinical features of fibromyalgia in systemic lupus erythematosus, systemic sclerosis and Sjögren's syndrome]. 61
12094151 2002
39
Exposure to solvents in female patients with scleroderma. 61
12086160 2002
40
Determination of autoantibodies to annexin XI in systemic autoimmune diseases. 61
11035417 2000
41
Increased in vitro production of interleukin 6 in response to trimethoprim among persons with trimethoprim induced systemic adverse reactions. 61
10606366 1999
42
Methotrexate-induced papular eruption in patients with rheumatic diseases: a distinctive adverse cutaneous reaction produced by methotrexate in patients with collagen vascular diseases. 61
10321597 1999
43
Lymphoscintigraphy in chyluria, chyloperitoneum and chylothorax. 61
9669413 1998
44
Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. 61
8929481 1996
45
Lymphocytes, cytokines, inflammation, and immune trafficking. 61
8941441 1996
46
[Clinical study on Fournier's gangrene--value of "through and through drainage"]. 61
7609356 1995
47
[A high-resolution computed tomographic study of the pulmonary interstitium in systemic autoimmune diseases]. 61
8128031 1994
48
Clinical, serological and immunogenetic features of Japanese anti-Ro/SS-A-positive patients with annular erythema. 61
8049546 1994
49
[Association of autoimmune disease in primary biliary cirrhosis]. 61
8114302 1994
50
[Detection of circulating antibodies in the blood and immune complex precipitates of patients with autoimmune diseases (preliminary report)]. 61
1579350 1992
Sources

Variations for Systemic Lupus Erythematosus 1

About this section

ClinVar genetic disease variations for Systemic Lupus Erythematosus 1:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TLR5 NM_003268.6(TLR5):c.1174C>T (p.Arg392Ter) SNV protective 6658 rs5744168 GRCh37: 1:223285200-223285200
GRCh38: 1:223111858-223111858
Sources

Expression for Systemic Lupus Erythematosus 1

About this section
Search GEO for disease gene expression data for Systemic Lupus Erythematosus 1.
Sources

Pathways for Systemic Lupus Erythematosus 1

About this section
Sources

GO Terms for Systemic Lupus Erythematosus 1

About this section
Sources

Sources for Systemic Lupus Erythematosus 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....